FDA to schedule panel review for Abbott's Xience stent

09/11/2007 | Wall Street Journal, The

The FDA plans to schedule an advisory panel review for Abbott Laboratories' Xience drug-coated coronary stent, an Abbott executive said. The company, which hopes to introduce the device in the U.S. in the first half of 2008, said it's working with the agency to schedule the meeting "as expeditiously as possible."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY